POT1

Across TCGA pan-cancer cohorts, POT1 mass-spec protein differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of POT1’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where POT1 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types POT1 is over-expressed in tumor, although a few such as LUAD and HNSC show the opposite, repressed pattern.

CCRCC, LUAD, and HNSC are the cancer types where POT1 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in POT1 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	All	All	+0.292	<.001	8	view →
LUAD	Female	All	−0.271	<.001	8	view →
HNSC	Male	III,IV	−0.243	<.001	8	view →
PDAC	All	II,III,IV	−0.380	<.001	7	view →
LSCC	All	All	−0.103	<.001	4	view →
OV	All	All	−0.528	.049	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

POT1–CCRCC

Open the CCRCC breakdown →